BIORESTORATIVE THERAPIES INC (BRTX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.15+2.99%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Reduce operating loss to better than -$3.4 million quarterly: Operating loss -5.3M vs target -3.4M.
The company is raising up to $1 million in loans. Revenue rose from $19,600 to $23,170 in one quarter. Operating losses improved by $439,567 in the same period. These show progress in fixing the business.
The company still loses money and revenue is small. The stock dropped 6% in one day. Directors resigned recently, which may hurt stability.
The price is about 10% above our fair value near $0. Analysts expect revenue to fall about 20%. We see some improvement but risks remain.
Breaks if: Loan agreement not secured or materially delayed within 12 months
Obtain new financing to support operations, including a revolving loan agreement with Bowery Group LLC for up to $1 million.
Newly stated in 2026-Q2. The company secured a revolving loan agreement with Bowery Group LLC for up to $1 million to support financing needs. This is a recent development with no prior quarters stating this priority, so trajectory is newly established.
“Company entered into a Revolving Loan Agreement with Bowery Group LLC for up to $1,000,000.”
Breaks if: Operating loss worsens beyond -$3,825,300
Breaks if: Quarterly revenue falls below $19,600
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity, as BRTX is in a volatile state with ongoing operating losses. The current thesis is cautious, given recent management changes and legal issues.
The market appears to have priced in a low level of fragility, suggesting that current valuations are justified compared to peers. However, there is a notable expectations gap, indicating that the market may not fully anticipate the challenges ahead.
Management is focused on improving revenue generation and managing operating losses, showing some progress in these areas. However, the company remains loss-making, and there is a high risk of missing earnings in the near term.
The long-term thesis hinges on the performance of sector bellwethers and the ability of BRTX to secure additional financing. Any shifts in the healthcare sector's momentum, either favorable or unfavorable, will significantly impact BRTX's trajectory.
In the next 1 to 3 years, BRTX's outlook is uncertain due to its financial challenges and external market factors. Not investment advice.
The most important moves since the prior daily snapshot.
Valuation fell by 29.8 points (from 48.3 to 18.5).
Signal changed from 'cautious' to 'restrictive'.
Composite insight fell by 10.7 points (from -23.1 to -33.8).
Yes, our read has weakened. The company suspended shipments of key products. This suspension impacts revenue generation and product availability. There are no new supportive factors noted.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.